151 related articles for article (PubMed ID: 37894699)
21. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
22. Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Nierman P
Clin J Oncol Nurs; 2021 Dec; 25(6):687-696. PubMed ID: 34800101
[TBL] [Abstract][Full Text] [Related]
23. A sensitive and rapid bioanalytical method for the quantitative determination of luliconazole in rabbit eye tissues using UPLC-MS/MS assay.
Yang J; Liang Z; Lu P; Song F; Zhang Z; Xia H; He J; Zhou T; Zhang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Apr; 1194():123173. PubMed ID: 35219088
[TBL] [Abstract][Full Text] [Related]
24. A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation.
Attwa MW; Darwish HW; Al-Shakliah NS; Kadi AA
Molecules; 2021 May; 26(9):. PubMed ID: 34063139
[TBL] [Abstract][Full Text] [Related]
25. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of LC-MS/MS method for determining the metabolic stability, pharmacokinetics, and dose proportionality of a novel anti-inflammatory cofilin inhibitor.
Alsegiani AS; Shah ZA
J Pharm Biomed Anal; 2023 Mar; 226():115258. PubMed ID: 36709658
[TBL] [Abstract][Full Text] [Related]
27. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
Delgado J; Josephson F; Camarero J; Garcia-Ochoa B; Lopez-Anglada L; Prieto-Fernandez C; van Hennik PB; Papadouli I; Gisselbrecht C; Enzmann H; Pignatti F
Oncologist; 2021 Mar; 26(3):242-249. PubMed ID: 33486852
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.
AlRabiah H; Kadi AA; Attwa MW; Mostafa GAE
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Oct; 1154():122195. PubMed ID: 32943176
[TBL] [Abstract][Full Text] [Related]
29. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
Shao Y; Xie S; Zhu H; Du X; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113355. PubMed ID: 32442869
[TBL] [Abstract][Full Text] [Related]
31. Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.
Edlund H; Buil-Bruna N; Vishwanathan K; Wei H; Raman R; de Kock M; He Z; Liu H; Baek M; Ware J; Patel P; Tomkinson H; Sharma S
Br J Clin Pharmacol; 2022 May; 88(5):2284-2296. PubMed ID: 34532877
[TBL] [Abstract][Full Text] [Related]
32. A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation.
Abdelhameed AS; Attwa MW; Al-Shaklia NS; Kadi AA
R Soc Open Sci; 2019 Jun; 6(6):190434. PubMed ID: 31312501
[TBL] [Abstract][Full Text] [Related]
33. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract][Full Text] [Related]
34. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
Eyre TA; Schuh A; Wierda WG; Brown JR; Ghia P; Pagel JM; Furman RR; Cheung J; Hamdy A; Izumi R; Patel P; Wang MH; Xu Y; Byrd JC; Hillmen P
Lancet Haematol; 2021 Dec; 8(12):e912-e921. PubMed ID: 34735860
[TBL] [Abstract][Full Text] [Related]
35. A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes.
Attwa MW; Abdelhameed AS; Alsaif NA; Kadi AA; AlRabiah H
RSC Adv; 2022 Jul; 12(31):20387-20394. PubMed ID: 35919584
[TBL] [Abstract][Full Text] [Related]
36. Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation.
Attwa MW; Alanazi MM
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838629
[TBL] [Abstract][Full Text] [Related]
37. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
38. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
[TBL] [Abstract][Full Text] [Related]
39. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Alsadhan A; Cheung J; Gulrajani M; Gaglione EM; Nierman P; Hamdy A; Izumi R; Bibikova E; Patel P; Sun C; Covey T; Herman SEM; Wiestner A
Clin Cancer Res; 2020 Jun; 26(12):2800-2809. PubMed ID: 32054731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
